Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
E RosenthalClaire Fougerou-LeurentA RenaultM P CarrieriF MarcellinR GarraffoE TeicherH AumaitreK LacombeF BaillyE BillaudS ChevaliezS DominguezM A ValantinJ ReynesA NaqviL CotteS MetivierV LeroyM DuponT AllegreP De TruchisV JeantilsJ ChasD Salmon-CeronP MorlatD NeauP PerréL PirothS PolM BourlièreG P PageauxL AlricD ZucmanP M GirardI Poizot-MartinY YazdanpanahF RaffiE Le PabicC TualA PailhéI AmriE BellissantJ M Molinanull nullPublished in: HIV medicine (2017)
LDV/SOF provided a high SVR rate in PI-experienced subjects coinfected with HCV genotype 1 and HIV-1, including patients with cirrhosis.